Max Hodak predicts that Cyens' in-house gene therapy will enter human trials within approximately one year
“we developed indigenously a state of the art gene therapy, which is probably going to humans next year”
→ Read the source episode
Our resolution criterion
disputableCyens' gene therapy enters human clinical trials
More from No Priors: Artificial Intelligence | Technology | Startups
Renee Haas predicts that within 5+ years, chip design from idea to GDS2 file will be possible for certain designs, likely using AI tooling.
Renee Haas predicts that semiconductor supply chain constraints will persist for 3-5 years at minimum.
Max Hodak predicts that the next version of Prima will enter human trials within approximately one year and expand addressable patient population to millions
Max Hodak predicts that Cyens will make first commercial sales of Prima in Europe within weeks of July 2026
Brian Armstrong predicts New Limit will launch its first phase one clinical trial for epigenetic reprogramming in the next year (2027).
Eric Alabest predicts chess.com will launch additional games beyond chess and poker
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.